Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $9.86.

Several analysts have commented on the stock. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. Wells Fargo & Company started coverage on Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price for the company. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, HC Wainwright decreased their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Savara Stock Performance

Shares of SVRA stock opened at $3.05 on Wednesday. The firm has a market capitalization of $523.44 million, a price-to-earnings ratio of -7.09 and a beta of 0.68. The stock has a fifty day moving average of $3.36 and a 200 day moving average of $3.91. Savara has a 52 week low of $2.82 and a 52 week high of $5.70. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). As a group, research analysts expect that Savara will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Savara

In other news, Director Joseph S. Mccracken purchased 20,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This represents a 10.48 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is owned by company insiders.

Institutional Trading of Savara

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its stake in shares of Savara by 12.5% in the second quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock worth $1,162,000 after purchasing an additional 32,142 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Savara by 967.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company’s stock valued at $177,000 after acquiring an additional 39,886 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after acquiring an additional 6,973 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Savara in the second quarter worth approximately $527,000. Finally, Choreo LLC purchased a new position in shares of Savara during the second quarter valued at approximately $59,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.